Skip to main content
Clinical Trials/ACTRN12612001157864
ACTRN12612001157864CompletedPhase 3

The effect of Prasugrel on Platelet – Lymphocyte Interactionsin Vascular disease

Capital and Coast District Heath Board0 sites24 target enrollmentStarted: October 31, 2012Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
24

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • Vascular population
  • *Patients on carotid surveillance programme with an identified carotid stenosis
  • *Patient is not on any antiplatelet therapy
  • Healthy population
  • *Healthy volunteers aged 18-45
  • *Not on any cardiovascular medication or immune modulating drugs.

Exclusion Criteria

  • Acute coronary syndrome within the preceding 3 months.
  • Intercurrent illness
  • Inability to provide written informed consent.
  • Compliance with follow-up likely to be inadequate
  • Known bleeding disorder
  • Platelet dysfunction
  • Recent surgery within 3 months
  • Allergy to Prasugrel
  • Administration of antiplatelet agent of NSAIDs in last 2 weeks

Investigators

Sponsor
Capital and Coast District Heath Board

Similar Trials